Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Dextenza in cataract surgery patients with mild dry eye
NCT04863742Phase 4Unknown
- Sponsor
- SightMD
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in dry eye syndrome (DED) and post-operative inflammation (2 arms), sponsored by SightMD. Primary endpoints: Best Corrected Visual Acuity (ETDRS) at Day 30, Uncorrected Visual Acuity at Day 30 and 1 more. Status: unknown.
02
Drugs
ozurdex
03
Conditions
dry eye syndrome (DED)post-operative inflammation
Beyond the preview
Go deeper on NCT04863742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863742.